Study of Toll-like Receptor 3 Gene Polymorphism as a Novel Risk Factor for HCV-related Hepatocellular Carcinoma in Egypt

2020 ◽  
Vol 20 (5) ◽  
pp. 382-389 ◽  
Author(s):  
Shimaa EL-Sharawy ◽  
Osama El- Sayed Negm ◽  
Sherief Abd-Elsalam ◽  
Hesham Ahmed EL-Sorogy ◽  
Mona Ahmed Helmy Shehata
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Factor ◽  
Gene Polymorphism ◽  
Clinical Laboratory ◽  
Treatment Options ◽  
Laboratory Evaluation ◽  
Toll Like Receptor ◽  
Focal Lesions ◽  
Tlr3 Gene ◽  
Cirrhotic Patients

Background & Aims: Hepatocellular carcinoma (HCC) is a highly aggressive cancer with few treatment options. Toll-like receptor 3 (TLR3) plays a key role in innate immunity and may affect the development of cancers. This study aimed to investigate the association between TLR3 gene polymorphism and HCV-related hepatocellular carcinoma in Egypt. Methods: This work was conducted on 70 individuals; fifty HCV cirrhotic patients were included in two groups; with HCC (30 patients) and without HCC (20 patients) compared with a group of 20 apparently healthy controls. All of the studied individuals underwent clinical-laboratory evaluation. TLR3 gene single-nucleotide polymorphism (SNP) (+1234C/T) was tested by polymerase chain reaction- restriction fragment length polymorphism. Results: This study reported that the prevalence of TLR3 +1234TT genotype was significantly increased in cirrhotic patients with HCC than without HCC, while it was not detected at all among the controls. When analyzing the TLR3 SNP +1234C/T with different clinical parameters in HCC patients, there was a significant association between+1234C/T SNP; namely TT genotype and each of the hepatic focal lesions᾽ number, size and the patients᾽ higher Okuda and BCLC stages. No association could be detected between TLR3 SNP and the age, sex, Child-Pugh grades, MELD score or AFP of the studied HCC cases. Conclusion: TLR3 gene SN P +1234C/T could be a novel risk factor for the HCV-related HCC among the Egyptian population.

Hepatocellular carcinoma in the non-cirrhotic liver

2021 ◽  
pp. 1-14
Author(s):  
Dong Yi ◽  
Wang Wen-Ping ◽  
Won Jae Lee ◽  
Maria Franca Meloni ◽  
Dirk-Andre Clevert ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Risk Factor ◽  
High Risk ◽  
Current Knowledge ◽  
Cirrhotic Liver ◽  
Imaging Features ◽  
Advanced Stage ◽  
High Risk Factor ◽  
Cirrhotic Patients

Liver cirrhosis is an established high-risk factor for HCC and the majority of patients diagnosed with HCC have cirrhosis. However, HCC also arises in non-cirrhotic livers in approximately 20 %of all cases. HCC in non-cirrhotic patients is often clinically silent and surveillance is usually not recommended. HCC is often diagnosed at an advanced stage in these patients. Current information about HCC in patients with non-cirrhotic liver is limited. Here we review the current knowledge on epidemiology, clinical features and imaging features of those patiens.

Treatment of patient with end-stage hepatocellular carcinoma by the mineral pulse light stimuli on LV acupoints- case report

2020 ◽  
Author(s):  
yongchol cha ◽  
Hyok Choe ◽  
Songjin Oh ◽  
ZinHwa Cha
Keyword(s):  
Hepatocellular Carcinoma ◽  
Light Stimulus ◽  
Treatment Options ◽  
Liver Malignancy ◽  
Pulse Light ◽  
Light Stimuli ◽  
Cirrhotic Patients ◽  
Light Stimulator ◽  
End Stage ◽  
High Degree

Abstract Background; Hepatocellular carcinoma (HCC) represents a major and steadily increasing global health challenge as the most common primary liver malignancy and leading cause of death in cirrhotic patients. The only hope for curative treatment or significant increase in life expectancy is early detection. Once patients have progressed towards end-stage HCC, effective treatment options are extremely limited on the background of a very high degree of heterogeneity in clinical presentation and outcome. Objectives; The purpose of this study is to perform clinical trial on an end-stage HCC patient by mineral pulse light stimulus on LV acupoints without any drugs use. Methods; End-stage HCC patient was stimulated by mineral pulse light stimulator (MPLS). Stimulus acupoints; LV3, LV14, SP6. The selected acupoints were stimulated by MPLS for 50~60 minutes once a day. The same method was performed on the patient for 25days and rested for 5days, and again repeated every month without any drugs use. Results; After treatment, the general patient conditions and alfa-fetoprotein level were improved and hepatoma size was decreased to 9.1×8.5cm from 11.0×9.7cm before treatment (a), and the decay areas was disappeared.Conclusions; End-stage HCC patient was improved by mineral pulse light stimulus on LV acupoints without any drugs use.

Early occurrence of hepatocellular carcinoma in patients with and without cirrhosis after HCV treatment with direct-acting antivirals.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 356-356
Author(s):  
Fabian Finkelmeier ◽  
Georg Dultz ◽  
Bernd Kronenberger ◽  
Kai Henrik Peiffer ◽  
Franziska Krauss ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Factor ◽  
Independent Risk Factor ◽  
De Novo ◽  
Direct Acting Antivirals ◽  
Historical Cohort ◽  
Comparison Results ◽  
Cirrhotic Patients ◽  
Direct Acting

356 Background: The aim of the study was to evaluate the risk of HCC development after treatment with direct-acting antivirals (DAA) and to compare hepatocellular carcinoma (HCC) occurrence to patients treated with interferon (IFN)-based therapies. Methods: We analyzed a large cohort with chronic HCV patients for the onset of new hepatocellular carcinoma after DAA treatment. A historic interferon treated cohort was investigated for comparison. Results: 819 patients were included in the DAA group, 269 (32.8%) had established cirrhosis. Median follow up was 263 days (0-1001). 25 patients (3.1%) were diagnosed with de novo HCC within the observation time. All of these patients had established cirrhosis. Patients with new HCC were mostly male, older, treatment experienced, had a lower SVR12 rate and higher levels of liver inflammation markers. Investigation of the subcohort of 269 cirrhotic patients yielded a HCC rate of 9.3% during the follow-up of approximately one year. Non-SVR12 was an independent risk factor for de novo HCC (OR 4.983, 1.39-17.88, 0.014). Most HCCs were diagnosed in early stage BCLC A. In the historical cohort of 351 IFN treated patients the rate of de novo HCC was 5.4% overall and 11.8% in patients with already established cirrhosis (n = 68). In the multivariate analysis failed SVR (OR 5.386, 1.155-25.108, p = 0.032) remained an independent risk factor for de novo HCC. In a combined analysis of all patients (DAA and IFN treated) in a multivariate approach male gender, failed SVR and cirrhosis were independent factors for HCC development. Conclusions: DAA treatment in cirrhotic patients does not seem to reduce the risk of HCC development in the short term. HCC rates were not different between DAA-treated patients and those who received interferon. Achievement of SVR seems to be the most important aim to prevent HCC development.

Post-resection recurrence of hepatocellular carcinoma in cirrhotic patients: Is thrombocytopenia a risk factor for recurrence?

2016 ◽  
Vol 25 (4) ◽  
pp. 364-369 ◽  
Author(s):  
Ahmed Shehta ◽  
Ho-Seong Han ◽  
Soyeon Ahn ◽  
Yoo-Seok Yoon ◽  
Jai Young Cho ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Factor ◽  
Cirrhotic Patients ◽  
Risk Factor For Recurrence

scholarly journals Serum level of cytokeratin 19 as a diagnostic and prognostic marker in patients with HCV-related hepatocellular carcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Maissa El Raziky ◽  
Hanan Abdel Hafez ◽  
Aisha Elsharkawy ◽  
Tarek Ahmed Moneer ◽  
Suzan M. EL-Sheikh ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Laboratory ◽  
Imaging Techniques ◽  
Intervention Group ◽  
Focal Lesion ◽  
Cytokeratin 19 ◽  
Predictive Values ◽  
Group I ◽  
Significant Difference ◽  
Cirrhotic Patients

Abstract Background The heterogeneous nature of human hepatocellular carcinoma (HCC) impedes both treatment strategies and prognostic predictions. Several markers have been proposed for the diagnosis of HCC. Cytoskeleton-associated proteins have been known as cellular integrators in neoplasm formation. Hepatic progenitor cells are thought to express alpha-fetoprotein (AFP) and hematopoietic as well as biliary markers such as cytokeratin 19 (CK 19) and cytokeratin 7. The aim of this study was to verify the role of serum CK 19 alone or in combination with AFP as a diagnostic marker of HCC and to assess the changes in its levels after ablation of HCV-related HCC to evaluate its role as a predictor marker for recurrence of HCC after ablation. The study was conducted on 102 HCV-related cirrhotic patients categorized into three different groups according to the clinical, laboratory, and radiological evaluation: group I—62 patients with early or intermediate HCC who underwent locoregional intervention, group II—20 patients with advanced HCC not fit for any intervention apart from best supportive treatment, and group III—20 cirrhotic patients with no evidence of HCC as proved by two imaging techniques. Results The mean serum levels of CK 19 were 6.5 ± 5.7, 10.5 ± 12.5, and 6.8 ± 2.8 ng/ml in groups I, II, and III, respectively, with no significant difference between groups. Sensitivity, specificity, positive, and negative predictive values of combined AFP and human CK 19 at cutoff levels of 25.5 ng/ml and 6.25 ng/ml were 93.9%, 45%, 87.5%, and 64.3%, respectively. In group I patients, CK 19 levels were comparable in patients with ablated focal lesion and those who did not at baseline; then, it was significantly higher in ablated patients than in patients with residual tumor 1 and 6 months after the intervention. Conclusions Combination of both AFP and CK 19 levels could increase the diagnostic accuracy of suspected HCCs. CK 19 levels are good predictors of ablation/recurrence in patients who underwent interventional procedures minimizing the need for follow-up imaging modalities.

Sign in / Sign up

Export Citation Format

Share Document